Abstract
Alzheimer’s disease (AD) is a complex neurodegenerative disorder with a multi-faceted pathogenesis. So far, the therapeutic paradigm “one-compound-one-target” has failed and despite enormous efforts to elucidate the pathophysiology of AD, the disease is still incurable.
The multiple factors involved in AD include amyloid aggregation to form insoluble neurotoxic plaques of Aβ, hyperphosphorylation of tau protein, oxidative stress, calcium imbalance, mitochondrial dysfunction and deterioration of synaptic transmission. These factors together, accentuate changes in the CNS homeostasis, starting a complex process of interconnected physiological damage, leading to cognitive and memory impairment and neuronal death.
A recent approach for the rational design of new drug candidates, also called multitarget-directed ligand (MTDL) approach, has gained increasing attention by many research groups, which have developed a variety of hybrid compounds acting simultaneously on diverse biological targets. This review aims to show some recent advances and examples of the exploitation of MTDL approach in the rational design of novel drug candidate prototypes for the treatment of AD.
Keywords: Alzheimer’s disease, multi-target directed drugs, neurodegenerative disorders, rational drug design.
Current Neuropharmacology
Title:Multi-Target Directed Drugs: A Modern Approach for Design of New Drugs for the treatment of Alzheimer’s Disease
Volume: 12 Issue: 3
Author(s): Kris Simone Tranches Dias and Claudio Viegas
Affiliation:
Keywords: Alzheimer’s disease, multi-target directed drugs, neurodegenerative disorders, rational drug design.
Abstract: Alzheimer’s disease (AD) is a complex neurodegenerative disorder with a multi-faceted pathogenesis. So far, the therapeutic paradigm “one-compound-one-target” has failed and despite enormous efforts to elucidate the pathophysiology of AD, the disease is still incurable.
The multiple factors involved in AD include amyloid aggregation to form insoluble neurotoxic plaques of Aβ, hyperphosphorylation of tau protein, oxidative stress, calcium imbalance, mitochondrial dysfunction and deterioration of synaptic transmission. These factors together, accentuate changes in the CNS homeostasis, starting a complex process of interconnected physiological damage, leading to cognitive and memory impairment and neuronal death.
A recent approach for the rational design of new drug candidates, also called multitarget-directed ligand (MTDL) approach, has gained increasing attention by many research groups, which have developed a variety of hybrid compounds acting simultaneously on diverse biological targets. This review aims to show some recent advances and examples of the exploitation of MTDL approach in the rational design of novel drug candidate prototypes for the treatment of AD.
Export Options
About this article
Cite this article as:
Simone Tranches Dias Kris and Viegas Claudio, Multi-Target Directed Drugs: A Modern Approach for Design of New Drugs for the treatment of Alzheimer’s Disease, Current Neuropharmacology 2014; 12 (3) . https://dx.doi.org/10.2174/1570159X1203140511153200
DOI https://dx.doi.org/10.2174/1570159X1203140511153200 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Docking-Related Survey on Natural-Product-Based New Monoamine Oxidase Inhibitors and Their Therapeutic Potential
Combinatorial Chemistry & High Throughput Screening Do Epigenetic Pathways Initiate Late Onset Alzheimer Disease (LOAD): Towards a New Paradigm
Current Alzheimer Research Clinical Applications of Mesenchymal Stem Cells in Laryngotracheal Reconstruction
Current Stem Cell Research & Therapy Past, Present and Future Drugs for the Treatment of Obsessive- Compulsive Disorder
Current Medicinal Chemistry Liposomes as siRNA Delivery Vectors
Current Drug Metabolism Amyotrophic Lateral Sclerosis: From Research to Therapeutic Attempts and Therapeutic Perspectives
Current Medicinal Chemistry Autophagy Modulators and Neuroinflammation
Current Medicinal Chemistry Ring Finger Ubiquitin Protein Ligases and Their Implication to the Pathogenesis of Human Diseases
Current Pharmaceutical Design Editorial (Hot Topic: Regenerative Medicine in Neurological Diseases)
Recent Patents on Regenerative Medicine Glia as a Turning Point in the Therapeutic Strategy of Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Recent Advances in Neuroinflammation Therapeutics: PPARs/LXR as Neuroinflammatory Modulators
Current Pharmaceutical Design Importance of Zebrafish as an Efficient Research Model for the Screening of Novel Therapeutics in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Targeting Stress Activated Protein Kinases, JNK and p38, as New Therapeutic Approach for Neurodegenerative Diseases
Central Nervous System Agents in Medicinal Chemistry Therapeutic Implications of Superoxide Dismutase And Its Importance in Kinase Drug Discovery
Current Topics in Medicinal Chemistry Current Evaluation of the Millennium Phytomedicine- Ginseng (II): Collected Chemical Entities, Modern Pharmacology, and Clinical Applications Emanated from Traditional Chinese Medicine
Current Medicinal Chemistry Disease-Specific iPS Cell Models in Neuroscience
Current Molecular Medicine Mechanism of Tau-Induced Neurodegeneration in Alzheimer Disease and Related Tauopathies
Current Alzheimer Research Nanowired Drug Delivery Across the Blood-Brain Barrier in Central Nervous System Injury and Repair
CNS & Neurological Disorders - Drug Targets Tryptophan Catabolites and Their Impact on Multiple Sclerosis Progression
Current Pharmaceutical Design Targeted Delivery for Neurodegenerative Disorders Using Gene Therapy Vectors: Gene Next Therapeutic Goals
Current Gene Therapy